Depression, Cytokines and Pancreatic Cancer

CompletedOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Pancreatic Cancer
Interventions
BEHAVIORAL

assessment interview and blood draw

All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

New York Presbyterian Hospital

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00582699 - Depression, Cytokines and Pancreatic Cancer | Biotech Hunter | Biotech Hunter